Skip to content
10-Q

Quarterly Report

Urovant Sciences Ltd.

0001564590-21-005814

← back to feed
Filed
Feb 12, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2020 · Feb 11, 2021 32.74M sh
Operating Cash Flow Q3 2020 · Dec 31, 2020 −$110.27M
Operating Cash Flow Q3 2020 · Dec 31, 2019 −$70.53M
Long Term Debt Q3 2020 · Dec 31, 2020 $209.29M
Cash And Equivalents Q3 2020 · Dec 31, 2020 $71.3M
Cash And Equivalents Q3 2020 · Mar 31, 2020 $51.41M
Stockholders Equity Q3 2020 · Dec 31, 2020 −$145.62M
Stockholders Equity Q3 2020 · Sep 30, 2020 −$113.05M
Stockholders Equity Q3 2020 · Jun 30, 2020 −$84.94M
Stockholders Equity Q3 2020 · Mar 31, 2020 −$58.01M
Stockholders Equity Q3 2020 · Dec 31, 2019 −$4.45M
Stockholders Equity Q3 2020 · Sep 30, 2019 $23.76M
Stockholders Equity Q3 2020 · Jun 30, 2019 $47.72M
Stockholders Equity Q3 2020 · Mar 31, 2019 $74.77M
Current Liabilities Q3 2020 · Dec 31, 2020 $40.44M
Current Liabilities Q3 2020 · Mar 31, 2020 $30.93M
Total Liabilities Q3 2020 · Dec 31, 2020 $254.5M
Total Liabilities Q3 2020 · Mar 31, 2020 $121.3M
Current Assets Q3 2020 · Dec 31, 2020 $86.05M
Current Assets Q3 2020 · Mar 31, 2020 $58.32M
Total Assets Q3 2020 · Dec 31, 2020 $108.89M
Total Assets Q3 2020 · Mar 31, 2020 $63.3M
Sga Expense Q3 2020 · Dec 31, 2020 $29.97M
Sga Expense Q3 2020 · Dec 31, 2020 $61.39M
Sga Expense Q3 2020 · Dec 31, 2019 $16.69M
Sga Expense Q3 2020 · Dec 31, 2019 $29.59M
Rd Expense Q3 2020 · Dec 31, 2020 $15.62M
Rd Expense Q3 2020 · Dec 31, 2020 $46.51M
Rd Expense Q3 2020 · Dec 31, 2019 $23.1M
Rd Expense Q3 2020 · Dec 31, 2019 $62.91M
Net Income Q3 2020 · Dec 31, 2020 −$46.8M
Net Income Q3 2020 · Dec 31, 2020 −$112.45M
Net Income Q3 2020 · Sep 30, 2020 −$35.16M
Net Income Q3 2020 · Jun 30, 2020 −$30.49M
Net Income Q3 2020 · Dec 31, 2019 −$41.26M
Net Income Q3 2020 · Dec 31, 2019 −$95.49M
Net Income Q3 2020 · Sep 30, 2019 −$25.74M
Net Income Q3 2020 · Jun 30, 2019 −$28.49M